[go: up one dir, main page]

MX2020001270A - Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39. - Google Patents

Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.

Info

Publication number
MX2020001270A
MX2020001270A MX2020001270A MX2020001270A MX2020001270A MX 2020001270 A MX2020001270 A MX 2020001270A MX 2020001270 A MX2020001270 A MX 2020001270A MX 2020001270 A MX2020001270 A MX 2020001270A MX 2020001270 A MX2020001270 A MX 2020001270A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
compositions
homologs
isoforms
Prior art date
Application number
MX2020001270A
Other languages
English (en)
Inventor
John Corbin
Courtney Beers
Vanessa Soros
Maria Kovalenko
Paul Fredrick Widboom
Joseph Robert Warfield
Original Assignee
Trishula Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trishula Therapeutics Inc filed Critical Trishula Therapeutics Inc
Publication of MX2020001270A publication Critical patent/MX2020001270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)

Abstract

En la presente invención se proveen anticuerpos que se unen selectivamente a CD39 y sus isoformas y homólogos, y composiciones que comprenden los anticuerpos. También se proveen métodos de uso de los anticuerpos, tales como métodos terapéuticos y de diagnóstico.
MX2020001270A 2017-07-31 2018-07-30 Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39. MX2020001270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762539527P 2017-07-31 2017-07-31
PCT/US2018/044449 WO2019027935A1 (en) 2017-07-31 2018-07-30 ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES

Publications (1)

Publication Number Publication Date
MX2020001270A true MX2020001270A (es) 2020-09-22

Family

ID=65233024

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001270A MX2020001270A (es) 2017-07-31 2018-07-30 Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.

Country Status (22)

Country Link
US (6) US20190062448A1 (es)
EP (1) EP3661966A4 (es)
JP (4) JP7113071B2 (es)
KR (2) KR20240153413A (es)
CN (2) CN118978594A (es)
AR (1) AR112639A1 (es)
AU (1) AU2018312251B2 (es)
BR (1) BR112020002012A8 (es)
CA (1) CA3071540A1 (es)
CL (1) CL2020000281A1 (es)
CO (1) CO2020001983A2 (es)
CR (1) CR20200101A (es)
DO (1) DOP2020000021A (es)
IL (2) IL316357A (es)
MX (1) MX2020001270A (es)
MY (1) MY202018A (es)
PE (1) PE20200617A1 (es)
PH (1) PH12020500240A1 (es)
SG (2) SG11202000820PA (es)
TW (2) TW202344516A (es)
WO (1) WO2019027935A1 (es)
ZA (1) ZA202000608B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2238170T3 (en) 2008-01-31 2017-02-27 Inserm - Inst Nat De La Santé Et De La Rech Médicale ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
IL316357A (en) 2017-07-31 2024-12-01 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP4043496A1 (en) * 2018-03-14 2022-08-17 Surface Oncology, Inc. Antibodies that bind cd39 and uses thereof
BR112020022371A2 (pt) 2018-05-03 2021-02-02 Shanghai Epimab Biotherapeutics Co., Ltd. anticorpos de alta afinidade para pd-1 e lag-3 e proteínas de ligação biespecífica produzidas a partir dos mesmos
MX2020012107A (es) 2018-06-18 2021-01-29 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2020172597A1 (en) * 2019-02-21 2020-08-27 Tizona Therapeutics Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies
EP4013788A1 (en) 2019-08-12 2022-06-22 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
KR20220050971A (ko) 2019-08-27 2022-04-25 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-cd39 항체
EP4031178A1 (en) * 2019-09-16 2022-07-27 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
TW202118791A (zh) 2019-11-05 2021-05-16 大陸商北京加科思新藥研發有限公司 對cd39具有特異性的結合分子及其用途
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3174202A1 (en) * 2020-04-03 2021-10-07 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and adoptive cell therapy
CN116209676A (zh) 2020-06-22 2023-06-02 恩格姆生物制药公司 Lair-1结合剂及其使用方法
WO2021260966A1 (ja) * 2020-06-25 2021-12-30 学校法人埼玉医科大学 アデノシン産生酵素を標的とする組成物
WO2022087458A1 (en) * 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
JP2023550832A (ja) * 2020-11-27 2023-12-05 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド ＣＤ３９およびＴＧＦβを標的とする新規のコンジュゲート分子
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
JP2024522069A (ja) 2021-05-19 2024-06-11 アシャ バイオセラピューティクス，インク． Ｉｌ－２１ポリペプチド及び標的化コンストラクト
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023138643A1 (zh) * 2022-01-24 2023-07-27 上海华奥泰生物药业股份有限公司 Cd39抗原结合蛋白及其应用
WO2023164872A1 (en) * 2022-03-03 2023-09-07 Arcus Biosciences, Inc. Anti-cd39 antibodies and use thereof
AR128688A1 (es) * 2022-03-03 2024-06-05 Arcus Biosciences Inc Anticuerpos anti-cd39 y uso de los mismos
US20250188165A1 (en) * 2022-03-04 2025-06-12 Trishula Therapeutics Inc Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer
US20250215105A1 (en) 2022-03-25 2025-07-03 Brightpath Biotherapeutics Co., Ltd. Anti-cd39 antibody
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
WO2024030956A2 (en) * 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
WO2024175760A1 (en) * 2023-02-24 2024-08-29 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis
CN119462929A (zh) * 2023-05-24 2025-02-18 深圳市先康达生命科学有限公司 靶向人Nectin4蛋白的抗体或其片段和应用
KR102879536B1 (ko) * 2023-06-09 2025-10-31 주식회사 브이티 시카 추출물이 함침된 마이크로 니들을 유효성분으로 포함하는 화장료 조성물 및 이의 제조방법
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN117986364B (zh) * 2023-12-27 2025-01-21 华润生物医药有限公司 特异性结合cd39的纳米抗体及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186745T1 (de) 1995-01-18 1999-12-15 Roche Diagnostics Gmbh Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
AU5265296A (en) 1995-04-10 1996-10-30 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
US6387645B1 (en) 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
IL140931A0 (en) 1998-07-16 2002-02-10 Hyseq Inc Methods and materials relating to novel cd39-like polypeptides
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6476211B1 (en) 1998-07-16 2002-11-05 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
US6350447B1 (en) 1999-01-29 2002-02-26 Hyseq, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6899875B1 (en) 1999-01-29 2005-05-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6780977B1 (en) 1999-01-29 2004-08-24 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6335013B1 (en) 1999-03-19 2002-01-01 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
AU2002361763A1 (en) 2001-12-17 2003-06-30 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
US20050037382A1 (en) 2003-04-08 2005-02-17 Robson Simon C. Methods and compositions for treating and preventing autoimmune disorders
WO2006111986A1 (en) 2005-04-19 2006-10-26 Fondazione Santa Lucia I.R.C.C.S. Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof
US9624309B2 (en) * 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
MX2010005683A (es) * 2007-11-30 2010-06-11 Bristol Myers Squibb Co Conjugados de anticuerpos anti-rg-1.
DK2238170T3 (en) 2008-01-31 2017-02-27 Inserm - Inst Nat De La Santé Et De La Rech Médicale ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
JP5882058B2 (ja) * 2008-11-07 2016-03-09 ファブラス エルエルシー 組合せ抗体ライブラリー及びその使用
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
CN104379601B (zh) * 2012-02-03 2021-04-09 霍夫曼-拉罗奇有限公司 双特异性抗体分子和抗原-转染的t-细胞以及它们在医药中的用途
PL3125927T3 (pl) * 2014-04-01 2021-07-19 Rubius Therapeutics, Inc. Sposoby i kompozycje do immunomodulacji
US10556959B2 (en) 2014-11-07 2020-02-11 Xencor, Inc. Anti-CD39 antibodies and uses thereof
SG10201913004UA (en) 2014-11-21 2020-03-30 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
US20180140724A1 (en) 2015-05-27 2018-05-24 The Trustees Of Columbia University In The City Of New York Tumor Deliverable Iron and Protein Synthesis Inhibitors as a New Class of Drugs for the Diagnosis and Treatment of Cancer
JP7023233B2 (ja) * 2015-10-01 2022-02-21 ポテンザ セラピューティックス インコーポレイテッド 抗ｔｉｇｉｔ抗原結合タンパク質と、その使用方法
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
JP2019509014A (ja) 2015-11-23 2019-04-04 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｃｄ３９血管アイソフォームターゲティング剤
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
EP3744348B1 (en) 2016-05-06 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml)
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
US10570167B2 (en) 2016-12-22 2020-02-25 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
IL316357A (en) 2017-07-31 2024-12-01 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CA3074588A1 (en) 2017-10-06 2019-04-11 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
KR102781619B1 (ko) 2017-11-15 2025-03-14 이나뜨 파르마 에스.에이. 암의 치료를 위한 인간 CD39 단백질의 ATPase 활성을 결합 및 저해하는 항체
EP4043496A1 (en) 2018-03-14 2022-08-17 Surface Oncology, Inc. Antibodies that bind cd39 and uses thereof
EP4013788A1 (en) 2019-08-12 2022-06-22 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
KR20220050971A (ko) 2019-08-27 2022-04-25 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-cd39 항체
EP4031178A1 (en) 2019-09-16 2022-07-27 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
CN110407941B (zh) 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途

Also Published As

Publication number Publication date
CR20200101A (es) 2020-04-15
CN111448211B (zh) 2024-06-07
US20250026850A1 (en) 2025-01-23
EP3661966A1 (en) 2020-06-10
IL272367A (en) 2020-03-31
IL272367B2 (en) 2025-08-01
WO2019027935A1 (en) 2019-02-07
US20210403593A1 (en) 2021-12-30
AU2018312251A1 (en) 2020-02-20
US20210009708A1 (en) 2021-01-14
ZA202000608B (en) 2022-07-27
CN118978594A (zh) 2024-11-19
PE20200617A1 (es) 2020-03-11
KR102718932B1 (ko) 2024-10-17
US20220340680A1 (en) 2022-10-27
CN111448211A (zh) 2020-07-24
CO2020001983A2 (es) 2020-04-01
JP2020530289A (ja) 2020-10-22
EP3661966A4 (en) 2021-07-21
US20220372163A1 (en) 2022-11-24
MY202018A (en) 2024-03-29
PH12020500240A1 (en) 2021-01-04
JP2022145720A (ja) 2022-10-04
JP2024079809A (ja) 2024-06-11
IL316357A (en) 2024-12-01
JP2025116106A (ja) 2025-08-07
RU2020108524A (ru) 2021-09-02
US20190062448A1 (en) 2019-02-28
JP7113071B2 (ja) 2022-08-04
KR20200033928A (ko) 2020-03-30
BR112020002012A2 (pt) 2020-09-01
TW202344516A (zh) 2023-11-16
CL2020000281A1 (es) 2020-12-18
CA3071540A1 (en) 2019-02-07
TWI798242B (zh) 2023-04-11
JP7690085B2 (ja) 2025-06-09
KR20240153413A (ko) 2024-10-22
IL272367B1 (en) 2025-04-01
SG11202000820PA (en) 2020-02-27
BR112020002012A8 (pt) 2022-06-28
SG10202111869SA (en) 2021-11-29
TW201920277A (zh) 2019-06-01
AR112639A1 (es) 2019-11-20
US11345757B2 (en) 2022-05-31
AU2018312251B2 (en) 2025-02-20
DOP2020000021A (es) 2020-08-16

Similar Documents

Publication Publication Date Title
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
WO2016077397A3 (en) Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
BR112017023868A2 (pt) anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
WO2016014434A3 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
MX2021007692A (es) Proteinas de union anti-pd-1 y metodos de uso de las mismas.
CO2019013718A2 (es) Anticuerpos anti-trkb
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
MX2021007846A (es) Proteinas que se unen a anti-pd-l1 y metodos de uso de las mismas.
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos
AR113007A1 (es) COMPOSICIONES DE HNF4A-saARN, Y MÉTODOS DE USO
EA202090552A1 (ru) Активируемые антитела к cd166 и способы их применения

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: TRISHULA THERAPEUTICS, INC.